A Phase 1 Study of Milademetan in Combination With Quizartinib in Patients With Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
doi: 10.1007/s10858-005-2590-6 Robson, Scott A., Gorbatyuk, Vitaliy Y., Maciejewski, Mark W
3007-A CLINICAL FEATURES OF ACUTE KIDNEY INJURY-NON HEPATORENAL SYNDROME VERSUS TYPE 1 HEPATORENAL SYNDROME IN PATIENTS WITH CIRRHOSIS AND ASCITES FROM A SINGLE QUATERNARY REFERRAL ACADEMIC CENTRE Neha Tiwari 1 , Chinmay Bera 2 , Cynthia Tsien 3 , Audrey Kapelera 1 , Nazia Selzner 3 and Florence Wong 1 , (1)Division of Gastroenterology and Hepatology, Toronto General Hospital, Toronto, ON, Canada, (2)University Health Network, (3)Ajmera Transplant Center, University of Toronto, Toronto, ON, Canada Background: The re-classification of renal dysfunction in cirrhosis to acute kidney injury (AKI), replacing type 1 hepatorenal (HRS1), is meant to lead to earlier diagnosis and treatment
Front Cell Dev Biol 8:597 Lang F, Lang KS, Lang PA, Huber SM, Wieder T (2006) Mechanisms and significance of eryptosis
Synergetic Supplement Timing Certain nutrients work well with glutathione
